SABCS 2021

Metformin is not an anti-cancer drug

Critical consideration of the study data is necessary

Re-evaluation confirms old data

Solved and unsolved controversies of early breast…

Molecular-guided treatment is of value in combination…

Hypothesis-generating study in the HER2-enriched…

The next standard for TNBC?!

Negative results with hope for translational projects

Genomic signatures of DCIS

Metformin shows no efficacy for most cancer patients

The risk-adapted decision for or against AI has to be…

Benefit only related to chemotherapy?!

Leading the way for other ct-DNA trials

"Signatures Genomiche " nel carcinoma duttale in situ

Kritische Betrachtung der Studiendaten notwendig

Negative Ergebnisse, aber Hoffnung für translationale…

Genomisch gesteuererte Therapie sinnvoll in Kombi mit…

Muss die risiko-adaptierte Entscheidungsfindung bei AI…

Erneute Auswertung bestätigt alte Daten

La metformina non può essere considerata un farmaco…

Hypothesen-generierende Studie beim HER2-enriched…

KEYNOTE-522 confirms ICI benefit in the neoadjuvant…

RxPONDER: Benefit only for pre-menopausal patients?…

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…

HR+ EBC: What about PALLAS/PENELOPE-B? What is the…

HER2+ EBC: Chemotherapy free regimens? Extended…

Switching with molecular progress improves PFS

More good news for TDXd

Samuraciclib - new targeted therapy for luminal breast…

Very good news for endocrine resistant metastatic…

TDXd is very efficient in patients with brain…

3 updates - 3 new standards of care

Dato-DXd new promising ADC

Precision oncology is beneficial in certain mBC…

TROP2 - new target for improved chemotherapy

PFS improvement with fulvestrant in patients with…

Pioneering study of personalized medicine in advanced…

Imaging with mass cytometry can provide predictive…

Activity of T-Dxd across all Her2-expressing breast…

Patients with BRCA2 don't show PFS benefit with CDK4/6i

Immuntherapy for high tumor mutation burden in…

Robust benefit of pembroluzimab in addition to…

IO + IO without resounding success in the mBC setting

Elacestrant - less than we expected

Chekpoint inhibition in breast cancer

Reconfirming effect of T-DXd in patients with brain…

Best of the year: systemic therapy

Effectiveness depending on PDL1 status

Promising results for TNBC patients

Dato-Dxd for metastatic TNBC

Final results of the CPS score subgroup analyses show…

Exciting novel therapies for metastatic TNBC

Oral SERDs are efficient, but show high progression…

Oral SERDs for early setting and adjuvant therapy

T-Dxd is also active in patients with brain metastasis

Pooled analyses shows OS benefit for most subgroups

My highlights of 2021 in metastatic breast cancer

Which patients will benefit from Pembro in metastatic…

Neues Target für optimierte Chemotherapie

Buone notizie per i tumori mammari endocrino resistenti

È un grande momento per i pazienti con tumore mammario…

Elacestrant – poniżej oczekiwań

Best of the Year: Systemtherapie

T-Dxd aktywny również w przerzutach do mózgu

Important benefice de l’ajout du pembrolizumab à la…

Amélioration de la survie sans progression par le…

IO + IO ohne durchschlagenden Erfolg beim mBC

Résultats prometteurs dans le cancer du sein triple…

Dato-DXd – nowy obiecujący koniugat przeciwciała i…

Checkpoint-Inhibition beim Mammakarzinom

Werden orale SERDs die Therapie mit Fulvestrant in…

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

Präzisionsonkologie funktioniert beim mBC

Samuracyklib – nowe leczenie celowane w rakach…

L’imaging mass cytometry può aiutare a predire…

Gepoolte Analyse zeigt OS Vorteil für fast alle…

Umstellung bei molekularem Progress verlängert PFS

Wegweisende Daten für die personalisierte Medizin beim…

Risultati promettenti nel tumore al seno triplo…

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…

Resultados finales de los análisis de los subgrupos de…

Wirksamkeit in Abhängigkeit von PDL1-Stautus

Mi retrospectiva del cáncer de mama metastático en 2021

Integrating patients perspectives in metastatic breast…

MBC HR+: What is the best option after a CDK4/6i…

MBC TNBC: Molecular tumor characteristics define the…

Treatment options for patients with metastatic TNBC

Therapy of brain metastasis – can T-DXd be the new SoC?

Targeting rare mutations in breast cancer - is this the…

Are SERDs a future therapy for endocrine resistant…